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DYNAMICS OF CALCIUM METABOLISM I N NEWBORNS (NB).
878 Mary 0. Lim and James W. Hansen (Spon. by P h i l i p M.
F a r r e l l ) , NICHD. NIH, Bethesda, MU.
The dynamics of calcium (Ca) metabolism i n NB a r e poorly d e f i n e d a l t h o u g h d i s o r d e r s a r e o f t e n encountered.
We s t u d i e d Ca dynamics i n NB t o improve o u r understanding of calcium physiology and p r o v i d e a r a t i o n a l b a s i s f o r therapy. An i n j e c t i o n of radioa c t i v e Ca-47 was g i v e n t o two NB monkeys and Ca-45 a d m i n i s t e r e d w i t h each f e e d i n g ; s p e c i f i c a c t i v i t i e s were determined i n plasma, f e c e s , and u r i n e . Risks o f r a d i o i s o t o p e s l e d u s t o t h e analogous u s e of s t a b l e Ca-46 and Ca-48 i n two low b i r t h weight i n f a n t s ; t h e s e were measured by mass spectrometry. Analysis by computer modeling gave t h e f o l l o w i n g r e s u l t s i n mglkglhr.
I n t a k e Absorp- .59 The observed s i m i l a r i t i e s between NB monkeys and humans i n t h e i r calcium metabolism s u g g e s t s t h i s l a b o r a t o r y animal is a n a p p r o p r i a t e model. The exchangeable calcium turnover r a t e i n NB i s 1 4 times t h e a d u l t r a t e , and bone calcium dynamics a r e l i k ew i s e a c c e l e r a t e d . Endogenous f e c a l Ca l o s s is a l s o markedly i n c r e a s e d i n NB d e s p i t e s i m i l a r i t i e s t o t h e a d u l t i n % a b s o r p t i o n and u r i n a r y e x c r e t i o n . These s t u d i e s demonstrate t h e v a l u e , s a f e t y , and p o t e n t i a l of s t a b l e i s o t o p e s i n d e f i n i n g Ca metabolism and d i s c l o s i n g r e l a t e d a b n o r m a l i t i e s i n human i n f a n t s . We a r e c u r r e n t l y a n a l y z i n g s i m i l a r d a t a from i n f a n t s w i t h short-gut syndrome and i s o l a t e d dermal o s s i f i c a t i o n . The e f f e c t o f v i t a m i n D on t h e s e q u e n t i a l changes i n serum calcium(Ca), phosphorus(P) and p a r a t h y r o i d honnone(1PTH) i n t h e f i r s t weeks o f l i f e is unknown. Two groups o f 6 2-3 day o l d p i g s from 4 l i t t e r s , r a i s e d i n a r e a s without u l t r a v i o l e t l i g h h w e r e f e d d i e t (Ca:P, 1 . 3 : l ) w i t h (Dl o r w i t h o u t (-Dl vitamin D. Weight, radiog r a p h i c changes i n t h e l o n g bones and changes i n Ca, P, iPTH and 25-hydroxyvitamin D (25-OH-D) were monitored weekly f o r 5 weeks and 2 weeks f o l l o w i n g t r e a t m e n t o f t h e -D group w i t h lo00 IU v i tamin ~3 d a i l y . Weight g a i n a t 7 weeks was t h e same i n D and -D p i g s (3.3 v s 2.9 x b a s e l i n e ) . I n -D p i g s , r a d i o g r a p h i c c h a n q e s o f r i c k e t s were p r e s e n t a t 3 weeks, c l i n i c a l s i g n s a t 4 weeks.
A p a t t e r n o f d e c r e a s i n g v a l u e s i n Ca, P, and iPTH wasobaerved i n b o t h groups t o t h e 4 t h week. T h e r e a f t e r , i n D p i g s , Ca and P r e t u r n e d t o p r e -d i e t v a l u e s , and iPTH s t a b i l i z e d a t v a l u e s 50% lower. -D p i g s showed g r e a t e r change* .ban D p i g s (average mg/dl d e c r e a s e from i n i t i a l v a l u e s ) : Ca a t week 1 11.05 v s . 0 2 ) ; P a t week 1 (2.43 v s . 6 4 ) , 2 (1.8 v s + . 7 2 ) , 3 (4.85 v s .98) a n d 4 (4.52 v s 1.18) and s m a l l e r d e c l i n e i n iPTH a t week 4 (48 v s 65% o f pred i e t v a l u e s ) . Hypocalcemia, hypophosphatemia, and a two-fold inc r e a s e i n serum iPTH p r e s e n t i n t h e -D group a t 5 weeks were normalized a f t e r t r e a t m e n t ; Ca remained s l i g h t l y low. 25-OH-D, 78% lower than maternal v a l u e s a t t h e s t a r t of t h e s t u d y , was not l e s s t h a n 5 ng/ml r e g u l a r l y i n -D p i g s u n t i l t h e 4 t h week.
I n n e o n a t a l p i g s , t h e d e c r e a s e i n serum phosphorus b e f o r e change i n iPTH i s an e a r l y f e a t u r e o f vitamin D d e f i c i e n c y , s u g g e s t i n g a d i r e c t r o l e o f vitamin D ; n t h e p h y s i o l o g i c hyperphosphatemia i n t h e v e r y young.
*I, v a l u e s range <.05 t o < 0 0 1 .
HYPERGLYCEMIA ASSOCIATED WITH HEMOLYTIC UREMIC SYN-
880 DROME. S h e r r y Loo, William H a r w n , and Kenneth H.
Cabbay, C h i l d r e n ' s H o s p i t a l Med. C t r . , D i v i s i o n s o f Endocr. and Nephr., Boston, HA. (Spon. by Warren E. Grupe).
Few r e p o r t s have l i n k e d g l u c o s e i n t o l e r a n c e t o a c u t e r e n a l f a i l u r e . We t h e r e f o r e e v a l u a t e d hyperglycemia (hGlu) noted i n a 3 y r .
o l d w h i t e male w i t h hemolytic uremic syndrome (HIJS) a f t e r i n s t i t u t i o n of p e r i t o n e a l d i a l y s i s f o r o l i q u r i a and subsequent
h e m d i a l y s i s . Blood g l u c o s e (BG) v a l u e s 2 1000 mg/dl and plasma glucagon l e v e l s of 2 1000 pg/ml were documented d u r i n g t h e o l ig u r i c s t a g e . Hyperglucagonemia (hGn) p e r s i s t e d b u t hGlu r e s o l v e d w i t h improvement i n r e n a l f u n c t i o n . I n s u l i n t h e r a p y was d i s c o nt i n u e d b e f o r e d i s c h a r g e a t which time blood g l u c o s e was normal, c r e a t i n i n e was 0.7, and t o t a l g l y c o s y l a t e d hemoglobin (Hgb A1) was 7.5% (nl-5-91.
Three d a y s a f t e r d i s c h a r g e hGlu was a g a i n documented, b u t subsequent followup demonstrated normal random g l u c o s e l e v e l s and e l e v a t e d glucagon v a l u e s . TW months l a t e r a random BG was 302 mg/dl and Hqb A1 was 11.3%. F a s t i n g BG was 109 mg/dl, i n c r e a s e d 1 h r p.c. t o 240 mg/dl, and remained e l e v a t e d f o r 1 0 hrs (191-385 mg/dl). Simultaneous i n s u l i n l e v e l s were 5 1 6 W/ml. I n t r a v e n o u s t o l b u t a m i d e and a r g i n i n e e a c h f a i l e d t o s t i m u l a t e i n s u l i n s e c r e t i o n . Glucagon l e v e l s a l s o d i d n o t i n c r e a s e a f t e r a r g i n i n e , whereas i n d i a b e t i c s a n e x c e s s reaponse is observed. W i l e g l u c o s e i n t o l e r a n c e and hGn have been documented i n c h r o n i c uremia i n a d u l t s , t h i s p a t i e n t c l e a r l y d i f f e r .
by showing b o t h hypoinsulinemia, hGn, and p e r s i s t e n t hGlu a f t e r r e t u r n o f normal r e n a l f u n c t i o n . The f i n d i n g s s u g g e s t a r o l e f o r a l t e r e d i s l e t c e l l f u n c t i o n s i n t h e p a t h o g e n e s i s of hyperglycamia a s s o c i a t e d w i t h HUS. As the role of placental glucose.6-phosphatasc is not known, children with this type of CSD ]nay be severely affected at birth. If ;he diagnosis can be made at that time, treatme~~ahould be instituted prophylactically before growth is further affected. We studied one symptomatic CSD infant, micmcephalic at birth, in whom the diagnosis was cstabWed by metabolic studies md liver biopsy (glucose-5-phosphatase activity < 5% of normal). Treatment. instituted at age 4% months, consisted of a glucou and low fat formula (Vivonex. 20 CPYOZ) given as a 12 hr contin. uous feeding with added calcium at night delivered vla gastrortomy and infusion pump. and two hourly daytime formula reedings plus sollds, wlth glucose as the only carbohydrate.
After one month of therapy. the initial hypoglycemia (< 25 mddl), hyperuricemia (7.9 mg/dl), lacticacidem~a (136 nddl), acidosis (C02 17 mM/L) and elevated liver enzymes had reverted to normal. Triglycerides (2 hr pc) remained elevated. Correction of the microcephaly was noted w~tiiin 6 weeks. and increase in weight velocity almost immediately after starting therapy. The child has been maintained on this feeding regime at home. Dcvelopmentally. at 37 weeks chronologic age, her adaptive behavior was at the 40 week level.
This case study implies that the placenta of this patient with Type I glycogen storage diseue did not contain glucose.6-phosphatase and therefore did not protect the fetus from intrauterine metabolic derangement which affected brain growth. Prophylactic neonatal dietary intervention prevented further deterioration and induced significant catch-up growth and is therefore recom. lnended for all future cases ~den~ified. F o u r m a l e p r o b a n d s p r e s e n t e d w i t h s e v e r e l e g b o w i n g a f t e r 1 y r o f a g e . D u r i n g 41 p a t i e n t -y r s o f o b s e r v a t i o n , l i n e a r q r o w t h r e m a i n e d n e a r t h e 3 r d p e r c e n t i l e ( T a n n e r c h a r t s ) ; b o n e X -r a y s s h o w o n l y c o a r s e t r a b e c u l a t i o n a n d s c l e r o s i s i n s t r e s s a r e a s . S e r u m [ P i ] i s < 1 mM, a s i t i s i n X -l i n k e d h y p o p h o s p h a t e m i a (XLH); TRPi i s s i g n i f i c a n t l y h i g h e r (76t7.3 p m o l e s / 1 0 0 ml GF) i n HBD t h a n i n X L H ( 3 1 t 2 . 8 u m o l e s / 1 0 0 ml GF, p c 0 . 0 1 ) a t t h e e q u i v a l e n t serum [ P i ] .
HYPOPHOSPHATEMIC BONE DISEASE (HBD)
T u b u l a r r e s p o n s e s t o b o v i n e PTH a n d TmPi a r e a b n o r m a l ( d e p r e s s e d ) i n H R D b u t d i f f e r e n t f r o m X L H . S e r u m iPTH a n d 25-OH0 a r e n o r m a l i n H B D . T h e e q u i v a l e n t h y p o p h o s p h a t e m i a s a r e c l e a r l y t h e r e s u l t o f d i f f e r e n t P i t r a n s p o r t d e f e c t s i n HBD a n d X L H ; t h e m o r e s e v e r e , r a c h i t i c b o n e d l s e a s e i n X L H p o i n t s t o a n a d d i t i o n a l d e f e c t i n v o l v i n g P i a c c e s s t o b o n e i n t h a t d i s e a s e . P e d i g r e e s t u d i e s i n d i c a t e t h a t H R D i s n o t X -l i n k e d ; o t h e r w i s e t h e i n h e r i t a n c e o f t h e c o n d i t i o n r e m a i n s u n c l e a r .
